Scientists at the Korea Research Institute of Bioscience and Biotechnology have developed a cutting-edge nanobody-based therapeutic modality specifically targeting lung cancer cells. The approach utilizes engineered single-domain antibodies that offer high specificity and penetration, enabling precise tumor targeting with potentially reduced off-target effects. This innovation marks a significant step forward in lung cancer immunotherapy, showcasing nanobodies’ versatility and clinical promise. The platform opens avenues for next-generation biologics optimized for cancer therapy, with potential applications across various solid tumors.